Drugs / recombinant human Thrombin
recombinant human Thrombin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04459871 | Nov 2019 → Oct 2021 | — | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human Thrombin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04459871 ↗ |
| Modality | Protein / enzyme biologic | “Biological: recombinant human Thrombin(CHO cell)” NCT04459871 ↗ |
| Route | Topical | “Topical Recombinant Human Thrombin(rhThrombin)” NCT04459871 ↗ |